These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 22389132)

  • 1. von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.
    James PD; Lillicrap D
    Am J Hematol; 2012 May; 87 Suppl 1(0 1):S4-11. PubMed ID: 22389132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.
    Castaman G; Federici AB; Bernardi M; Moroni B; Bertoncello K; Rodeghiero F
    J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology, diagnosis, and management of von Willebrand disease in India.
    Ghosh K; Shetty S
    Semin Thromb Hemost; 2011 Jul; 37(5):595-601. PubMed ID: 22102205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis and management of von Willebrand disease].
    Higasa S; Tokugawa T; Sawada A
    Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring Therapy during Treatment of von Willebrand Disease.
    Favaloro EJ; Pasalic L; Curnow J
    Semin Thromb Hemost; 2017 Apr; 43(3):338-354. PubMed ID: 27472426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
    Castaman G; Federici AB; Rodeghiero F; Mannucci PM
    Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients.
    Federici AB; Bucciarelli P; Castaman G; Baronciani L; Canciani MT; Mazzucconi MG; Morfini M; Rocino A; Schiavoni M; Oliovecchio E; Iorio A; Mannucci PM
    Semin Thromb Hemost; 2011 Jul; 37(5):511-21. PubMed ID: 22102194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guidelines for the diagnosis and management of von Willebrand disease in Italy.
    Federici AB; Castaman G; Mannucci PM;
    Haemophilia; 2002 Sep; 8(5):607-21. PubMed ID: 12199668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and management of von Willebrand disease in Australia.
    Favaloro EJ; Bonar R; Favaloro J; Koutts J
    Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New advances in the diagnosis of von Willebrand disease.
    Sharma R; Haberichter SL
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):596-600. PubMed ID: 31808831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.
    Lillicrap D
    Blood; 2013 Nov; 122(23):3735-40. PubMed ID: 24065240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of inherited von Willebrand disease in 2007.
    Federici AB; Mannucci PM
    Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.
    Lillicrap D
    Hematology Am Soc Hematol Educ Program; 2013; 2013():254-60. PubMed ID: 24319188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Von Willebrand's disease: case report and review of literature.
    Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M
    Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.